These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23072522)

  • 1. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.
    Chinnock R; Webber SA; Dipchand AI; Brown RN; George JF;
    Am J Transplant; 2012 Nov; 12(11):3061-8. PubMed ID: 23072522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
    J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
    Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
    Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.
    Hayes D; Breuer CK; Horwitz EM; Yates AR; Tobias JD; Shinoka T
    Pediatr Cardiol; 2015 Dec; 36(8):1748-53. PubMed ID: 26187515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr Virus Predicts Malignancy After Pediatric Heart Transplant, Induction Therapy and Tacrolimus Don't.
    Giuliano K; Canner JK; Scully BB; Clarke N; Fraser CD; Ravekes W; Mettler B; Jacobs ML; Sen DG
    Ann Thorac Surg; 2022 Nov; 114(5):1794-1802. PubMed ID: 34563503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG; Tan MYQ; Quak SH; Aw MM
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
    Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
    Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study.
    Cupit-Link MC; Nageswara Rao A; Warad DM; Rodriguez V; Khan S
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):e473-e478. PubMed ID: 29620685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.